Boyden Finds Digital Progress Puts Europe in Pole Position to Champion Industry 5.0
Global research shows Industry 5.0 gathering pace as European business leaders excel in leveraging digital capabilities through human ingenuity
NEW YORK and LONDON and BERLIN, Nov. 20, 2022 (GLOBE NEWSWIRE) -- Boyden, a premier leadership and talent advisory firm with more than 75 offices in over 45 countries, reports on its annual global executive talent research. Findings show European respondents focusing on key elements of Industry 5.0, striving for growth through (i) innovation, (ii) digital transformation and (iii) human capital.
The global study, Strengthening the human-centric core of Industry 5.01, How can organisations thrive in a complex world of risk? explores perspectives on risk among CEOs, boards and other senior leaders, alongside executive talent trends, priorities and investment.
“Despite economic and geopolitical concerns, European business leaders are pressing ahead with an integrated strategy of growth through innovation and digital advances combined with human ingenuity,” comments Kathleen Dunton, Boyden board member, Managing Partner Germany and EMEA Regional Practice Leader, Private Equity & Venture Capital. “Investment in talent is spread across leadership development, hiring new leaders, retraining and interim management. In this tough environment, leaders are resilient, leveraging their most valuable soft skills identified by our respondents as driving change, inspiring teams and showing empathy.”
Findings that show how European organisations are well positioned for Industry 5.0:
- A stronger focus than other regions on strengthening tech/cloud/cybersecurity and digital skills in 2022, consistent with 2021 findings
- Structural change driven by digital advances and competing for the right talent, identified by 43 percent and 33 percent of respondents respectively
- Exceptionally high confidence among respondents in the technology sector, with 94 percent very confident/confident in their organisation’s growth potential, while concerned externally about (i) geopolitical risk, (ii) industry competition and (iii) national economic volatility
- Greater investment in leadership development of high potentials through 2023
- Culture shifts driven by organisational agility and innovation, identified by 44 percent and 40 percent of respondents respectively
- Overall confidence in organisational growth potential (where there is the greatest element of control) at 80% very confident/confident
Mark Soden, Managing Partner at Boyden UK and member of the global technology practice adds, “Despite the economic and geopolitical headwinds, it is no surprise that the technology sector continues to remain confident; customer demand is strong and there is still plenty of investor appetite. While some areas of technology may face a challenging 2023 there will be pockets of the sector that continue to thrive.”
An increase in senior-level recruitment is expected through 2023, up from 35 percent of respondents in the 2021 study to 52 percent in 2022, correlating with human capital as the third top driver of growth. Recruitment challenges are expected by 64 percent compared with 48 percent in 2021, with an expected increase in the use of interim managers; 36 percent of respondents are extremely likely/likely to bring in interim executives in Europe, up from 22 percent in 2021. Financial services is the sector most likely to increase engagement of interims.
Lourdes Lopez, Partner at Boyden Spain shares senior recruitment advice, “Top talent in the technology and tech-driven sectors will be attracted to human-centric companies offering innovation, creativity and a strong strategy for facing new challenges. This is a key moment for reinforcing leadership teams. Top executives are more open to disruptive projects and will do proper due-diligence before joining. So transparent and clear communication from the early stages is essential, as well as a good understanding of candidates’ main motivations.”
Findings on how organisations are approaching ESG show that for 60 percent of respondents ESG-sustainability is ‘part of most business discussions’ or ‘deeply embedded in organisational culture’; and for 51 percent of respondents ESG-DE&I is ‘part of most business discussions’ or ‘deeply embedded in organisational culture’.
ESG is very much a focus and priority at board level. Exploring skills most in need of strengthening on the board shows (i) 60 percent of respondents identify ESG-DE&I; (ii) 50 percent ESG-sustainability; and (iii) 47 percent innovation/business transformation.
Read the full report: Europe Regional Analysis: Strengthening the human-centric core of Industry 5.0
About the research
This research was conducted in Q2 2022 among senior executives worldwide from publicly-quoted, private/independent, private/family owned, social enterprise and PE-backed organisations. A total of 640 complete responses include 33 percent from Europe, where respondents are 31 percent board/president/CEOs; 21 percent SVP, division or country heads; and 40 percent functional leaders.
Boyden is a premier leadership and talent advisory firm with more than 75 offices in over 45 countries. Our global reach enables us to serve client needs anywhere they conduct business. We connect great companies with great leaders through executive search, interim management and leadership consulting solutions. For further information, visit www.boyden.com.
|Joanna Goncalves, Boyden|
Global Senior Director of Marketing
T: +1 416 214 4208
1 The Fifth Industrial Revolution, also known as Industry 5.0, is a new phase of industrialisation, whereby humans work alongside advanced technologies and AI-powered robots to enhance processes within the workplace. Source: The Manufacturer. Source: https://www.themanufacturer.com/articles/the-innovation-behind-the-industrial-revolution/
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/101b0304-75d8-4702-8581-4ced62fa391fTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful
Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release
At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t